Print

Pluristem Therapeutics (PSTI) Provides Update on Clinical Status of IC Trials  
6/19/2013 9:24:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAIFA, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, provided an update today on the status of its clinical trials in Intermittent Claudication (IC):

Help employers find you! Check out all the jobs and post your resume.

//-->